Reference Module in Biomedical Sciences 2014
DOI: 10.1016/b978-0-12-801238-3.00203-8
|View full text |Cite
|
Sign up to set email alerts
|

Principles of Toxicology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 28 publications
(3 citation statements)
references
References 13 publications
0
2
0
Order By: Relevance
“…In this sense, an important parameter is the therapeutic index (TI), which is a quantitative relationship between the efficacy and safety of a drug [51] . Mathematically, the TI is the ratio between the dose expected to elicit some adverse effect and the dose needed to elicit bioactive effects: [52] …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In this sense, an important parameter is the therapeutic index (TI), which is a quantitative relationship between the efficacy and safety of a drug [51] . Mathematically, the TI is the ratio between the dose expected to elicit some adverse effect and the dose needed to elicit bioactive effects: [52] …”
Section: Resultsmentioning
confidence: 99%
“…In this sense, an important parameter is the therapeutic index (TI), which is a quantitative relationship between the efficacy and safety of a drug. [51] Mathematically, the TI is the ratio between the dose expected to elicit some adverse effect and the dose needed to elicit bioactive effects: [52] TI ¼ that the tested sample is more active than toxic, while a TI < 1 reflects that the toxic dose is lower than the bioactive dose. All the studied samples had previously demonstrated their high potential to inhibit ChEs.…”
Section: Comparison Of a Salina And Mtt Toxicity Assaysmentioning
confidence: 99%
“…Показано, что достижение терапевтического эффекта в популяции на уровне 60 % уже приводит к проявлениям побочных эффектов в «чувствительной» субпопуляции. В отличие от терапевтических эффектов, в побочные реакции, как правило, вовлечено большее количество молекулярных мишеней и биохимических процессов [19]. Полиморфизм генов, кодирующих цитохромы Р450, может выступать в качестве фактора, с которым связаны эти реакции, так как в метаболизме лекарств, применяемых в схемах химиотерапии лимфомы Ходжкина ABVD и BEACOPP участвует большое количество цитохромов Р450 [3].…”
Section: обсуждение / Discussionunclassified